In my view, GSK is definitely interested, but the disagreement is the price. They probably don't anticipate a large percentage of patients with triglycerides in the 200-500 range opting for medication ie Vascepa. And moreover, as williams has repeatedly pointed out Lovaza sales already include 50% off label use, eventhough Lovaza is not approved for the Anchor indication.
One more thing. Do you think that given the lack of correlation of clinical outcome with other triglyceride lowering drugs, BP has become a bit less enthusiastci of triglyceride lowering drugs, ie Vascepa. Also--who knows if the REDUCE IT study will come up positive.
Lovasa did close to a billion in sales, but maybe BP doesn't expect that to continue?